Research may explain how the body’s foremost anti-cancer ‘guardian’ protein learned to switch sides

CSHL's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

PostDateIconTuesday, 29 July 2014 14:15 Print


Switching sides  1  - sordellaThe protein p53-psi, a variant of the well-known anti-cancer guardian protein p53, can reprogram cells to "switch sides" and acquire pro-metastatic features. Two types of cells that don't naturally express p53-psi (LEFT panel) exhibit changes in shape (RIGHT panel) characteristic of the transition to metastasis when they are made to express p53-psi.

Cold Spring Harbor, NY -- Researchers at Cold Spring Harbor Laboratory (CSHL) have discovered a new function of the body’s most important tumor-suppressing protein. Called p53, this protein has been called “the guardian of the genome.” It normally comes to the fore when healthy cells sense damage to their DNA caused by stress, such as exposure to toxic chemicals or intense exposure to the sun’s UV rays.  If the damage is severe, p53 can cause a cell to commit preprogrammed cell-death, or apoptosis.  Mutant versions of p53 that no longer perform this vital function, on the other hand, are enablers of many different cancers.

Cancer researcher Dr. Raffaella Sordella, a CSHL Associate Professor, and colleagues, today report in Proceedings of the National Academy of Sciences the discovery of a p53 cousin they call p53Ψ (the Greek letter “psi”).  It is a previously unknown variant of the p53 protein, generated by the same gene, called TP53 in humans, that gives rise to other forms of p53. 

Sordella and colleagues observed that p53Ψ, when expressed, reduces the expression of a molecular glue called E-cadherin, which normally keeps cells in contact within epithelial tissue, the tissue that forms the lining of the lung and many other body organs.  This is accompanied by expression of key cellular markers associated with tumor invasiveness and metastatic potential. (These are markers of EMT, or epithelial-to-mesenchymal transition.) Consistently, Sordella and her team found levels of p53Ψ to be elevated  in early-stage lung tumors with poor prognosis.
switching-sides-2---sordellaTwo types of cells that don't naturally express p53-psi (LEFT panel) exhibit changes in shape (RIGHT panel) characteristic of the transition to metastasis when they are made to express p53-psi. Careful investigation revealed that p53Ψ generates pro-growth effects by interacting with a protein called cyclophillin D (CypD), at the membrane of the cell’s energy factories, the mitochondria, and by spurring the generation of oxidizing molecules called reactive oxygen species (ROS).

p53Ψ was found by the team to be inherently expressed in tumors but also in injured tissue. “This is intriguing,” Sordella says, “because generation of cells bearing characteristics of those seen in wound healing has been seen previously, in tumors.” 

It is possible, Sordella says, that more familiar p53 mutants associated with tumor growth and metastasis may have “hijacked” those abilities from the program used by p53Ψ to promote healing during tissue injury.  A cellular program, in other words, that evolved over eons to heal may have been hijacked by mutant p53 to enable cancers to spread out of control.

The team is currently investigating p53Ψ in wound healing to help clarify its role.  Confirmation would lend support to the theory that mutant p53 hijacks that function to help advance pro-metastatic processes in cancer.

The research discussed in this release was funded by a grant from the Damon Runyon Cancer Research Foundation.  

“p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state” appears online ahead of print the week of July 28, 2014 in Proceedings of the National Academy of Sciences.  The authors are: Serif Senturk, Zhan Yao, Matthew Camiolo, Brendon Stiles, Trushar Rathod, Alice M. Walsh, Alice Nemajerova, Matthew J. Lazzara, Nasser K. Altorki, Adrian Krainer, Ute M. Moll, Scott W. Lowe, Luca Cartegni and Raffaella Sordella.  The paper can be obtained at: http://www.pnas.org/content/early/recent

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for the impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 600 researchers and technicians strong and its Meetings & Courses program hosts more than 12,000 scientists from around the world each year to its Long Island campus and its China center. For more information, visit www.cshl.edu.

News Source : Research may explain how the body’s foremost anti-cancer ‘guardian’ protein learned to switch sides
Copy this html code to your website/blog to embed this press release.